Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Phase 2 Completed 10 enrolled Memorial Sloan Kettering Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Timeline

Start: 2019-07-31
Primary completion: 2026-06-01
Completion: 2026-06-01

Publications

Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	—
Subject	Nivolumab	Monoclonal antibody	480 mg	—

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Summary

Timeline

Publications

Drugs

Indications